21 CFR 610.42
§ 610.42 Restrictions on use for further manufacture of medical devices.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 610.42, § 610.42 Restrictions on use for further manufacture of medical devices, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/88429
- Permanent ID
ys:prov:88429@1- SHA-256
dfb70e4b4273da88af144bd7bbbb9ff6b5320a83938ddd4f91f0126cd5566ab1
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) In addition to labeling requirements in subchapter H of this chapter, when a medical device contains human blood or a blood component as a component of the final device, and the human blood or blood component was found to be reactive by a screening test performed under § 610.40(a) and (b), then you must include in the device labeling a statement of warning indicating that the product was manufactured from a donation found to be reactive by a screening test for evidence of infection due to the identified relevant transfusion-transmitted infection(s).
(b) FDA may approve an exception or alternative to the statement of warning required in paragraph (a) of this section based on evidence that the reactivity of the human blood or blood component in the medical device presents no significant health risk through use of the medical device.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.